Erythropoietin (Y-shaped pegylation) - Xiamen Amoytop Biotech/BioGeneric Pharma

Drug Profile

Erythropoietin (Y-shaped pegylation) - Xiamen Amoytop Biotech/BioGeneric Pharma

Alternative Names: YPEG-EPO; YPEG-rhEPO

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xiamen Amoytop Biotech
  • Class Antianaemics; Erythropoietins
  • Mechanism of Action Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Anaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Anaemia(In volunteers) in China (SC, Injection)
  • 15 Mar 2016 Biomarkers information updated
  • 30 Sep 2012 Phase-I clinical trials in Anaemia (In volunteers) in China (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top